Drug Profile
Avosentan
Alternative Names: R 639; RO 67-0565; SPP 301Latest Information Update: 26 Aug 2011
Price :
$50
*
At a glance
- Originator Roche
- Developer Speedel Pharmaceuticals
- Class Cardiovascular therapies; Pyridines; Pyrimidines; Sulfonamides
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic nephropathies
Most Recent Events
- 07 May 2009 No development reported - Phase-II for Diabetic nephropathies in European Union (PO)
- 09 Jul 2008 Speedel has been acquired by Novartis
- 19 Jun 2008 Preclinical pharmacodynamics data presented at the 18th European Society of Hypertension and the 22nd Scientific Meeting of the International Society of Hypertension (HYP-2008) ,,,